These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 25488861)
21. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Adjei AA Clin Lung Cancer; 2005 Nov; 7(3):221-3. PubMed ID: 16354319 [TBL] [Abstract][Full Text] [Related]
22. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Ciuffreda L; Incani UC; Steelman LS; Abrams SL; Falcone I; Curatolo AD; Chappell WH; Franklin RA; Vari S; Cognetti F; McCubrey JA; Milella M Curr Pharm Des; 2014; 20(24):3944-57. PubMed ID: 24138714 [TBL] [Abstract][Full Text] [Related]
23. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Imperial R; Toor OM; Hussain A; Subramanian J; Masood A Semin Cancer Biol; 2019 Feb; 54():14-28. PubMed ID: 29175106 [TBL] [Abstract][Full Text] [Related]
25. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Guin S; Theodorescu D Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115 [TBL] [Abstract][Full Text] [Related]
26. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Ross SJ; Revenko AS; Hanson LL; Ellston R; Staniszewska A; Whalley N; Pandey SK; Revill M; Rooney C; Buckett LK; Klein SK; Hudson K; Monia BP; Zinda M; Blakey DC; Lyne PD; Macleod AR Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615361 [TBL] [Abstract][Full Text] [Related]
27. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Bugaj LJ; Sabnis AJ; Mitchell A; Garbarino JE; Toettcher JE; Bivona TG; Lim WA Science; 2018 Aug; 361(6405):. PubMed ID: 30166458 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Tolcher AW; Khan K; Ong M; Banerji U; Papadimitrakopoulou V; Gandara DR; Patnaik A; Baird RD; Olmos D; Garrett CR; Skolnik JM; Rubin EH; Smith PD; Huang P; Learoyd M; Shannon KA; Morosky A; Tetteh E; Jou YM; Papadopoulos KP; Moreno V; Kaiser B; Yap TA; Yan L; de Bono JS Clin Cancer Res; 2015 Feb; 21(4):739-48. PubMed ID: 25516890 [TBL] [Abstract][Full Text] [Related]
29. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Schildhaus HU; Schultheis AM; Rüschoff J; Binot E; Merkelbach-Bruse S; Fassunke J; Schulte W; Ko YD; Schlesinger A; Bos M; Gardizi M; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Hekmat K; Frank KF; Reiser M; Schulz H; Krüger S; Stoelben E; Zander T; Wolf J; Buettner R Clin Cancer Res; 2015 Feb; 21(4):907-15. PubMed ID: 25492085 [TBL] [Abstract][Full Text] [Related]
30. Metformin-associated lactic acidosis and temporary ileostomy: a case report. Margiani C; Zorcolo L; Mura P; Saba M; Restivo A; Scintu F J Med Case Rep; 2014 Dec; 8():449. PubMed ID: 25526771 [TBL] [Abstract][Full Text] [Related]
31. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Lin JJ; Gallagher EJ; Sigel K; Mhango G; Galsky MD; Smith CB; LeRoith D; Wisnivesky JP Am J Respir Crit Care Med; 2015 Feb; 191(4):448-54. PubMed ID: 25522257 [TBL] [Abstract][Full Text] [Related]
32. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Chapman PB; Solit DB; Rosen N Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746 [TBL] [Abstract][Full Text] [Related]
33. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381 [TBL] [Abstract][Full Text] [Related]
34. Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression. Rushworth LK; Kidger AM; Delavaine L; Stewart G; van Schelven S; Davidson J; Bryant CJ; Caddye E; East P; Caunt CJ; Keyse SM Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18267-72. PubMed ID: 25489104 [TBL] [Abstract][Full Text] [Related]
35. Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. van der Mijn JC; Sol N; Mellema W; Jimenez CR; Piersma SR; Dekker H; Schutte LM; Smit EF; Broxterman HJ; Skog J; Tannous BA; Wurdinger T; Verheul HM J Extracell Vesicles; 2014; 3():25657. PubMed ID: 25491250 [TBL] [Abstract][Full Text] [Related]
36. Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan. Vogelhuber M; Feyerabend S; Stenzl A; Suedhoff T; Schulze M; Huebner J; Oberneder R; Wieland W; Mueller S; Eichhorn F; Heinzer H; Schmidt K; Baier M; Ruebel A; Birkholz K; Bakhshandeh-Bath A; Andreesen R; Herr W; Reichle A Cancer Microenviron; 2015 Apr; 8(1):33-41. PubMed ID: 25503648 [TBL] [Abstract][Full Text] [Related]
37. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Gamba S; Camaj P; Heinemann V; Laubender RP; Wang Y; Zhao Y; Stintzing S; Giessen C; Boeck S; Haertl C; Bruns CJ; Modest DP Anticancer Drugs; 2015 Apr; 26(4):371-8. PubMed ID: 25514114 [TBL] [Abstract][Full Text] [Related]
38. Metformin and survival in diabetic patients with breast cancer. El-Benhawy SA; El-Sheredy HG J Egypt Public Health Assoc; 2014 Dec; 89(3):148-53. PubMed ID: 25534180 [TBL] [Abstract][Full Text] [Related]
39. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. Ying M; Zhu X; Chen K; Sha Z; Chen L J Cancer Res Clin Oncol; 2015 Aug; 141(8):1427-39. PubMed ID: 25577224 [TBL] [Abstract][Full Text] [Related]